Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

Data ReadoutnegativeivonescimabCelldex drugGilead HIV tabletNegative

AI Analysis

Summary

Celldex's drug failed a skin disease study, while Summit's ivonescimab analysis addresses investor skepticism about PD-1/VEGF combination approaches. Gilead and Merck unveiled data for new once-weekly HIV treatment and a psychedelics candidate.

Outcome Details

Celldex drug failed skin disease study

Importance:5/10

Sentiment:

-0.30

PD-1/VEGFclinical trial failureHIVpsychedelicsdata readout

Related Companies

$CLDX $GILD $MRK

Read the original article

Published by BioPharma Dive on July 22, 2026 1:33 PM

Read Original